Background
==========

Esophageal cancer is the fourth leading cause of cancer death in the People's Republic of China. In contrast to Western countries, esophageal squamous cell carcinoma (ESCC) continues to be the predominant subtype in Chinese population, with a high burden of morbidity and mortality.[@b1-ott-9-4257]--[@b3-ott-9-4257] Despite the increasing availability of treatments and anticancer drugs, the prognosis of ESCC remains unfavorable, with a 5-year overall survival (OS) rate of \<40%.[@b3-ott-9-4257] The Tumor-Node-Metastases (TNM) staging system is widely used to stratify survival in ESCC.[@b4-ott-9-4257] In addition to the TNM system, various factors have been studied in attempts to predict prognosis in clinical practice more accurately. Recently, a series of inflammatory biomarkers have been identified as prognostic factors in patients with ESCC and other cancers, such as Glasgow Prognostic Score (GPS) and neutrophil/lymphocyte ratio (NLR).[@b5-ott-9-4257]--[@b10-ott-9-4257] These inflammatory prognostic biomarkers have been increasingly appreciated, as they could be easily calculated and feasibly operated in clinical practice.

Cumulative evidence has identified tobacco smoking and alcohol drinking as significant risk factors for ESCC.[@b1-ott-9-4257],[@b11-ott-9-4257]--[@b16-ott-9-4257] However, the prognostic value of smoking and drinking in ESCC has been less discussed. Few studies have been reported for esophageal cancer, though the data varied widely. In 2008, a study from Sweden showed that smoking was an unfavorable prognostic factor for ESCC.[@b17-ott-9-4257] Similar findings were reported by Japanese authors in 2009.[@b18-ott-9-4257] However, an Australian study then demonstrated that heavy consumption of alcohol but not smoking was associated with worse prognosis in ESCC.[@b19-ott-9-4257] In 2013, two Chinese studies declared conflicting findings regarding this issue. Zhang et al[@b2-ott-9-4257] reported that neither smoking nor drinking predicted 2-year OS or disease-free survival (DFS) in ESCC patients from Shandong province. Another study demonstrated that drinking, smoking, and areca chewing were all significant prognostic factors in ESCC patients from Taiwan province.[@b20-ott-9-4257]

Therefore, we conducted this clinical study to explore the prognostic value of smoking and drinking in a consecutive cohort of Chinese patients with locoregional ESCC who underwent surgery-based curative therapy. The objectives of the study were to evaluate the prognostic value of tobacco smoking and alcohol drinking and to investigate their relationships with other clinicopathological characteristics.

Patients and methods
====================

Ethics statement
----------------

All patients provided authorized and written informed consent for their information to be stored in the Sun Yat-Sen University Cancer Center database and to be used for research. Study approval was obtained from an independent ethics committee at the Cancer Center of Sun Yat-Sen University. The study was undertaken in accordance with the ethical standards of the World Medical Association's Declaration of Helsinki. All the methods were carried out in accordance with the approved guidelines.

Patients
--------

A consecutive cohort of patients who attended Sun Yat-Sen University Cancer Center between January 2007 and December 2008 was analyzed retrospectively. Four hundred eighty-eight cases who met the following criteria were included in the study: 1) the disease was pathologically diagnosed as ESCC and evaluated clinically to be at a localized or locoregional stage (stages I--III according to the sixth edition of the American Joint Committee on Cancer \[AJCC\]/Union for International Cancer Control \[UICC\] TNM system); 2) complete clinical data and disease records were available; and 3) the disease was managed with radical esophagectomy.

Basic demographics (sex, age), details of medical history and medications, and baseline tumor characteristics (grade and stage) were collected for all patients ([Table 1](#t1-ott-9-4257){ref-type="table"}). Heavy smoking was defined as ≥20 lifetime pack-years.[@b18-ott-9-4257] Alcohol drinkers were defined as patients who consumed any alcoholic beverage once or more per week.[@b14-ott-9-4257],[@b20-ott-9-4257] On cessation of treatment, each patient was followed up every 3 months at the clinic or by telephone contact and interviewed for at least 5 years. The last follow-up date was July 31, 2014.

Statistical analysis
--------------------

Relationships between smoking and drinking status and clinicopathological variables were assessed by chi-square test. Survival time was calculated from the date of diagnosis to the date of death or the last follow-up. For patients who remained alive, data were censored at the date of last contact. For the analysis of DFS, events were defined as the first locoregional recurrence or distant tumor relapse or death from any cause. Kaplan--Meier method was used to estimate the 5-year OS and 5-year DFS; log-rank test was used to determine survival differences between subgroups differing in exposure to heavy smoking and/or drinking. Cox proportional hazards models were used for univariate and multivariate analyses to determine hazard ratios (HRs) for variables with respect to OS and DFS. HRs with 95% confidence intervals (CIs) and two-sided *P*-values were reported. Alpha values of *P*\<0.05 were considered statistically significant. All statistical analyses were performed using SPSS Version 19.0 (IBM Corporation, Armonk, NY).

Results
=======

Patient characteristics and treatments
--------------------------------------

The characteristics of the study population are presented in [Table 1](#t1-ott-9-4257){ref-type="table"}. Data for 488 ESCC patients were analyzed (369 men and 119 women). The median age at presentation with cancer was 59 years (mean 58.4 years). Tumors were pathologically confirmed as being of highly or moderately differentiated grade in 378 patients (77.4%). Three hundred seven tumors (62.9%) were limited to the middle third of the esophagus. A total of 43 (8.8%), 228 (46.7%), and 217 (44.5%) patients were categorized as having AJCC/UICC stage I, stage II, and stage III disease, respectively. GPS and NLR were calculated to evaluate the systemic inflammatory status of each patient.[@b5-ott-9-4257]--[@b7-ott-9-4257] Baseline GPSs were 0, 1, and 2 in 379 (77.7%), 95 (19.5%), and 14 (28.6%) patients, respectively. At initial diagnosis, 247 patients had NLR \<2 and 241 had NLR ≥2. Of the 488 patients included in the study, 250 (51.2%) were heavy smokers and 165 were alcohol drinkers (33.8%).

A total of 247 heavy smokers and 163 drinkers were male patients, representing a significant male predominance. Compared with never-smokers and light smokers, heavy smokers were more likely to have advanced TNM stage (*P*=0.007) and higher NLR at initial diagnosis (*P*=0.014). Compared with nondrinkers, alcohol drinkers were more likely to have advanced TNM stage (*P*=0.010), to present with a larger tumor (*P*=0.023), and to undergo multidisciplinary treatment (*P*=0.009).

All patients (n=488) underwent radical esophagectomy. A total of 385 (78.9%) patients underwent radical esophagectomy alone and 103 (21.1%) underwent radical esophagectomy combined with multimodal treatment. Adjuvant treatments were chemotherapy in 69 patients, chemoradiotherapy in 12 patients, and radiotherapy in three patients. Thirteen patients received neoadjuvant concurrent chemoradiotherapy, five underwent neoadjuvant chemotherapy, and one received neoadjuvant radiotherapy. The most common chemotherapeutic agents administered in various combinations were docetaxel (n=52), nedaplatin (n=48), cisplatin (n=30), fluorouracil (n=27), and paclitaxel (n=16). Docetaxel plus nedaplatin (n=34) was the most commonly used regimen.

Survival analysis
-----------------

Median follow-up time was 44 months (range 1--90 months). During the follow-up period, 228 patients died from ESCC and 13 patients died from cardiovascular diseases, pulmonary diseases, and treatment-related toxicity. Median DFS and survival time for the entire patient group were 43.2 months and 59.3 months, respectively. Three-year and 5-year DFS rates were 52.7% and 42.4%, respectively; 3-year and 5-year survival rates were 59.7% and 49.6%, respectively.

In a Cox univariate model for DFS, tumor grade, tumor length, TNM stage, treatment approach, smoking status, and drinking status were all significant prognostic factors. Because both heavy smoking and drinking are risk factors for ESCC, we further explored the impact of combined heavy smoking and drinking on DFS and OS. Combined exposure (both heavy smoking and drinking) was significantly associated with impaired DFS on univariate analysis (*P*=0.022, HR =1.400, 95% CI =1.051--1.865). Median DFS was 58.5 months for patients who neither smoked heavily nor drank (neither-users) and 30.9 months for those exposed to both, with 5-year DFS rates of 48.5% and 35.1%, respectively ([Figure 1](#f1-ott-9-4257){ref-type="fig"}). On multivariate analysis of DFS, both tumor grade and TNM stage were shown to be independent prognostic factors. However, combined exposure failed to independently predict unfavorable DFS on multivariate analysis ([Table 2](#t2-ott-9-4257){ref-type="table"}).

Univariate analysis of OS indicated that tumor length, TNM stage, treatment, GPS, smoking status, drinking status, and combined exposure status significantly predicted the clinical outcome of ESCC. Compared with neither-users, the crude HRs for those using one or both substances were 1.367 and 1.578, respectively (both *P*\<0.05). Multivariate analysis of OS was then performed using a Cox proportional hazards model. After adjusting for tumor length, clinical stage, treatment, and GPS, we found that patients who both smoked heavily and drank had a 1.392 times greater risk of dying during follow-up compared with neither-users (95% CI =1.020--1.901, *P*=0.037). As expected, TNM stage was the most significant predictor of OS. TNM stage III (*P*\<0.001, HR =2.387, 95% CI =1.814--3.141) was an independent predictor of poor OS. For neither-users, either-users, and users of both heavy tobacco and alcohol, the 5-year OS rates and OS times were 57.4%, 46.4%, and 39.1% (*P*\<0.05) and not reached, 55.2 months, and 41.2 months (*P*\<0.05), respectively ([Figure 2](#f2-ott-9-4257){ref-type="fig"}). Although a trend toward worse outcome was found, GPS 2 was not significantly associated with OS after adjusting for other covariates (*P*=0.056; [Table 3](#t3-ott-9-4257){ref-type="table"}).

Discussion
==========

In this study, we found significantly worse OS in ESCC patients with a history of both heavy smoking and drinking, even after consideration of clinical data such as disease stage and GPS. Importantly, this finding was obtained in a cohort of patients who underwent radical surgery. Our results suggest that combined exposure to both heavy smoking and drinking might substantially affect tumor progression in ESCC patients treated with radical surgery. Our study included an adequately large and representative sample, comprehensively reflecting ESCC in the People's Republic of China.

To our knowledge, this is one of the largest studies worldwide investigating the influence of smoking and drinking on ESCC survival. Few studies have explored the prognostic value of smoking and drinking in ESCC. In 2008, Swedish authors reported data from a nationwide case--control study demonstrating that ESCC patients with a history of smoking (HR =2.1, 95% CI =1.0--4.4) had a worse outcome on subset analysis.[@b17-ott-9-4257] Alcohol consumption was not a significant predictor of survival in that study. However, most of the patients enrolled in the Swedish study had adenocarcinoma of the esophagus and gastric cardia and only 20% of their cases underwent esophagectomy.[@b17-ott-9-4257] In contrast, we studied ESCC patients who had all undergone radical surgery and excluded those with esophageal adenocarcinoma. Another case--control study of an Australian population found that heavy consumption of alcohol but not smoking predicted an unfavorable prognosis in ESCC patients.[@b19-ott-9-4257] In that study, only 42% of the patients underwent resection and \>30% were not treated with curative intent. Moreover, the study did not provide complete clinical data for all patients. For almost 50% of the patients included, information on AJCC stage was insufficient.

In addition to reports from Western countries, there have also been studies in Eastern countries where ESCC is relatively prevalent. Shitara et al[@b18-ott-9-4257] conducted a retrospective study in a Japanese population and found that smoking history strongly predicted poor prognosis in ESCC patients; 364 cases were included in this study and the results showed that heavy smoking increased the mortality risk to 1.73 (95% CI =1.12--2.68, *P*=0.013) compared with nonsmokers. Importantly, the effect of the interaction between heavy smoking and treatment with chemoradiotherapy on the prognosis of 195 ESCC patients was determined. No prognostic effect of heavy smoking was detected in 168 ESCC patients treated with surgery or endoscopic mucosal resection. Alcohol drinking was also investigated in this study, but no significant findings were obtained. Wu et al[@b20-ott-9-4257] retrospectively analyzed data from 718 ESCC patients from Taiwan and discussed the prognostic effect of lifestyle factors. Habitual alcohol drinking was shown to be the strongest predictor of ESCC survival. Combined exposure to drinking, smoking, and areca chewing was an independent predictor of worse prognosis in ESCC patients. However, Wu et al's study included more cases of advanced ESCC (n=506, 70.6%) than were included in our study and no information on cancer treatment was provided. In view of the ethnic and epidemiological similarity between our patients and patients of that study, we selected the same cutoff to identify drinkers. Recently, a Chinese study of 79 ESCC patients (four in stage IV) managed with primary radiotherapy reported that neither smoking nor drinking was associated with prognosis in ESCC, though any effect of smoking or drinking on prognosis might have been shadowed by the small sample size.[@b2-ott-9-4257]

In this study, combined exposure to both heavy smoking and alcohol drinking significantly increased the risk of death to 1.392 compared with neither-users. We focused on a patient population with nonmetastatic ESCC who were treated with radical esophagectomy, reflecting the real clinical entity of ESCC in the People's Republic of China. Our inclusion criteria largely reduced any potential selection bias. However, a history of combined exposure seemed not to be linked to DFS in the ESCC patients in our study. More adjuvant treatments were prescribed for alcohol drinkers (n=46, 27.9%, *P*=0.009) and for heavy smokers (n=60, 24%, *P*=0.108). The relatively more advanced stage of ESCC in heavy smokers and drinkers might explain this finding.

The exact mechanism by which exposure to both tobacco and alcohol leads to worse survival in ESCC remains unknown. This phenomenon is likely to occur for many reasons. First, cumulative exposure to both tobacco and alcohol impairs the individual's immune system and nutritional status, leading to a systemic inflammatory response.[@b21-ott-9-4257]--[@b23-ott-9-4257] Our data show that heavy smokers were more likely to have higher NLR at initial diagnosis (*P*\<0.05). A consequence of these alterations in immune function and nutritional status would be a decrease in the effectiveness of treatment and an increase in the incidence of treatment-related complications. In addition, consumption of alcohol or nicotine can lead to molecular and genetic changes in tumor cells. Overexpression of DNA repair enzymes caused by heavy smoking has been observed in esophageal cancer, resulting in poor response to chemotherapy.[@b24-ott-9-4257]--[@b26-ott-9-4257] Smoking produces hypoxia and thus influences the radiosensitivity and promotes the angiogenesis of ESCC.[@b27-ott-9-4257] p53 mutation was reported to be more common in heavy smokers.[@b28-ott-9-4257],[@b29-ott-9-4257] Alcohol has been found to induce a more aggressive phenotype in ESCC tumors. Coupled with genetic alterations in acetaldehyde elimination modulated by alcohol dehydrogenase 1B (ADH1B) and aldehyde dehydrogenase 2 (ALDH2), tumors develop and spread aggressively, resulting in younger age at diagnosis of ESCC.[@b12-ott-9-4257],[@b30-ott-9-4257] Our data suggest that both heavy smoking and alcohol drinking are significantly associated with advanced clinical stage at initial diagnosis of ESCC (both *P*\<0.05). Furthermore, alcohol drinking was found to be associated with larger tumor size (\>3 cm) at baseline. We might conclude that the complex genetic/molecular changes caused by both heavy smoking and drinking promote the development of ESCC and thus affect its prognosis.[@b15-ott-9-4257],[@b24-ott-9-4257],[@b25-ott-9-4257],[@b31-ott-9-4257] Finally, heavy smoking and drinking can lead to other diseases that could contribute to earlier death from ESCC,[@b17-ott-9-4257] which could be partly supported by our results. Among patients who both smoked heavily and drank, three patients died from cardiovascular diseases, five died from pulmonary diseases, and one died from chemotherapy-related toxicity. In contrast, among those who neither smoked heavily nor drank, only one patient died from cardiovascular diseases. This is a possible explanation for our finding that combined exposure was associated with OS but not DFS.

Our study has limitations. We investigated the prognostic impact of smoking and alcohol status at baseline but did not obtain sufficient information concerning the smoking and drinking behaviors of our ESCC patients. Moreover, there are other factors we should take into account, for example, continuing or stopping the use of tobacco or alcohol during treatment is a critical issue.

Conclusion
==========

Our results indicate that combined exposure to both heavy smoking and drinking might be predictive of poor prognosis in ESCC patients. This finding could be helpful for the management of ESCC patients with respect to their tobacco and alcohol use. Collection of detailed information on smoking and drinking should be considered in prospective studies of ESCC in the future. For ESCC patients who are both heavy smokers and drinkers, more frequent follow-up and more aggressive treatment are recommended. Our findings need to be validated in future studies and the molecular/genetic mechanism of the effect of smoking and drinking on ESCC should be further elucidated and interpreted.
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###### 

Baseline patient demographics and tumor characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics    Total      Heavy smoking   *χ*^2^\       Drinking                                             *χ*^2^\                     
                                                *P*-value                                                          *P*-value                   
  ------------------ ---------- --------------- ------------- ---------------------------------------------------- ------------- ------------- ----------------------------------------------------
  Sex                                                         \<0.001[\*](#tfn1-ott-9-4257){ref-type="table-fn"}                               \<0.001[\*](#tfn1-ott-9-4257){ref-type="table-fn"}

   Male              369        247 (66.9%)     122 (33.1%)                                                        163 (44.2%)   206 (55.8%)   

   Female            119        3 (2.5%)        116 (97.5%)                                                        2 (1.7%)      117 (98.3%)   

  Age (years)                                                 0.968                                                                            0.218

   Mean ± SD         58.4±9.2   58.3±8.6        58.6±9.8                                                           57.4±8.1      58.9±9.6      

   Median            59.00      59              59                                                                 58            59            

   \<60              262        134 (55.1%)     128 (48.9%)                                                        95 (36.3%)    167 (63.7%)   

   ≥60               226        116 (51.3%)     110 (48.7%)                                                        70 (31.0%)    156 (69.0%)   

  Tumor grade                                                 0.939                                                                            0.465

   I--II             378        194 (51.3%)     184 (48.7%)                                                        131 (34.7%)   247 (65.3%)   

   III               110        56 (50.9%)      54 (49.1%)                                                         34 (30.9%)    76 (69.1%)    

  Tumor location                                              0.209                                                                            0.439

   Upper             42         20 (47.6%)      22 (52.4%)                                                         13 (31.0%)    29 (69.0%)    

   Middle            307        150 (48.9%)     157 (51.1%)                                                        99 (32.2%)    208 (67.8%)   

   Lower             139        80 (57.6%)      59 (42.4%)                                                         53 (38.1%)    86 (61.9%)    

  Tumor length                                                0.639                                                                            0.023[\*](#tfn1-ott-9-4257){ref-type="table-fn"}

   ≤3 cm             251        126 (50.2%)     125 (49.8%)                                                        73 (29.1%)    178 (70.9%)   

   \>3 cm            237        124 (52.3%)     113 (47.7%)                                                        92 (38.8%)    145 (61.2%)   

  TNM stage                                                   0.007[\*](#tfn1-ott-9-4257){ref-type="table-fn"}                                 0.010[\*](#tfn1-ott-9-4257){ref-type="table-fn"}

   I                 43         17 (39.5%)      26 (60.5%)                                                         11 (25.6%)    32 (74.4%)    

   II                228        105 (46.1%)     123 (53.9%)                                                        65 (28.5%)    163 (71.5%)   

   III               217        128 (59.0%)     89 (41.0%)                                                         89 (41.0%)    128 (59.0%)   

  Treatment                                                   0.108                                                                            0.009[\*](#tfn1-ott-9-4257){ref-type="table-fn"}

   Surgery alone     385        190 (49.4%)     195 (50.6%)                                                        119 (30.9%)   266 (69.1%)   

   Surgery + RT/CT   103        60 (58.3%)      43 (41.7%)                                                         46 (44.7%)    57 (55.3%)    

  GPS                                                         0.092                                                                            0.334

   0                 379        186 (49.1%)     193 (50.9%)                                                        125 (33.0%)   254 (67.0%)   

   1                 95         58 (61.1%)      37 (38.9%)                                                         37 (38.9%)    58 (61.1%)    

   2                 14         6 (42.9%)       8 (57.1%)                                                          3 (21.4%)     11 (78.6%)    

  NLR                                                         0.014[\*](#tfn1-ott-9-4257){ref-type="table-fn"}                                 0.291

   \<2               247        113 (45.7%)     134 (54.3%)                                                        78 (31.6%)    169 (68.4%)   

   ≥2                241        137 (56.8%)     104 (43.2%)                                                        87 (36.1%)    154 (63.9%)   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*\<0.05.

**Abbreviations:** SD, standard deviation; RT, radiotherapy; CT, chemotherapy; GPS, Glasgow Prognostic Score; NLR, neutrophil/lymphocyte ratio; TNM, Tumor-Node-Metastases.

###### 

Univariate and multivariate analyses of DFS in 488 ESCC patients

  Characteristics              Median DFS   5-year DFS   Univariate             Multivariate                                                              
  ---------------------------- ------------ ------------ ---------------------- -------------------------------------------------- ---------------------- ----------------------------------------------------
  Sex                                                                           0.110                                                                     
   Male                        37.5         40.6         1                                                                                                
   Female                      58.5         46.9         0.796 (0.601--1.053)                                                                             
  Age (years)                                                                   0.358                                                                     
   \<60                        39.0         40.1         1                                                                                                
   ≥60                         50.2         43.9         0.896 (0.708--1.133)                                                                             
  Tumor grade                                                                   0.030[\*](#tfn3-ott-9-4257){ref-type="table-fn"}                          0.032[\*](#tfn3-ott-9-4257){ref-type="table-fn"}
   I--II                       48.6         45.6         1                                                                         1                      
   III                         31.6         30.9         1.343 (1.029--1.752)                                                      1.338 (1.025--1.746)   
  Tumor location                                                                                                                                          
   Upper                       28.9         39.7         1                                                                                                
   Middle                      43.9         42.1         0.877 (0.577--1.333)   0.539                                                                     
   Lower                       36.8         43.3         0.900 (0.573--1.413)   0.646                                                                     
  Tumor length                                                                  0.020[\*](#tfn3-ott-9-4257){ref-type="table-fn"}                          0.197
   ≤3 cm                       50.9         45.7         1                                                                         1                      
   \>3 cm                      30.8         39.0         1.322 (1.046--1.671)                                                      1.170 (0.922--1.484)   
  TNM stage                                                                     \<0.001                                                                   \<0.001[\*](#tfn3-ott-9-4257){ref-type="table-fn"}
   I--II                       NR           55.6         1                                                                         1                      
   III                         20.8         25.1         2.414 (1.902--3.062)                                                      2.255 (1.754--2.897)   
  Treatment                                                                     0.010[\*](#tfn3-ott-9-4257){ref-type="table-fn"}                          0.609
   Surgery alone               48.6         45.1         1                                                                         1                      
   Surgery + RT/CT             23.7         32.6         1.426 (1.088--1.869)                                                      1.076 (0.812--1.426)   
  GPS                                                                                                                                                     
   0                           48.6         44.7         1                                                                                                
   1                           30.8         35.3         1.283 (0.963--1.710)   0.089                                                                     
   2                           23.6         21.4         1.752 (0.955--3.213)   0.070                                                                     
  NLR                                                                           0.131                                                                     
   \<2                         49.7         44.7         1                                                                                                
   ≥2                          31.6         39.5         1.198 (0.948--1.513)                                                                             
  Heavy smoking                                                                 0.045                                                                     
   No                          55.1         46.9         1                                                                                                
   Yes                         34.7         37.5         1.272 (1.005--1.619)                                                                             
  Drinking                                                                      0.041[\*](#tfn3-ott-9-4257){ref-type="table-fn"}                          
   No                          50.8         45.9         1                                                                                                
   Yes                         30.9         35.3         1.288 (1.010--1.643)                                                                             
  Heavy smoking and drinking                                                                                                                              
   Neither                     58.5         48.5         1                                                                         1                      
   Either                      37.9         39.2         1.299 (0.982--1.720)   0.067                                              1.213 (0.915--1.608)   0.179
   Both                        30.9         35.1         1.400 (1.051--1.865)   0.022[\*](#tfn3-ott-9-4257){ref-type="table-fn"}   1.242 (0.929--1.660)   0.143

**Note:**

*P*\<0.05.

**Abbreviations:** DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; RT, radiotherapy; CT, chemotherapy; GPS, Glasgow Prognostic Score; NLR, neutrophil/lymphocyte ratio; TNM, Tumor-Node-Metastases.

###### 

Univariate and multivariate analyses of OS in 488 ESCC patients

  Characteristics              Median OS   5-year OS   Univariate             Multivariate                                                                
  ---------------------------- ----------- ----------- ---------------------- ---------------------------------------------------- ---------------------- ----------------------------------------------------
  Sex                                                                         0.236                                                                       
   Male                        55.1        48.2        1                                                                                                  
   Female                      NR          52.4        0.834 (0.617--1.126)                                                                               
  Age (years)                                                                 0.376                                                                       
   \<60                        64.9        51.2        1                                                                                                  
   ≥60                         55.1        47.1        1.121 (0.871--1.443)                                                                               
  Tumor grade                                                                 0.069                                                                       
   I--II                       66.8        51.9        1                                                                                                  
   III                         44.1        40.2        1.306 (0.979--1.741)                                                                               
  Tumor location                                                                                                                                          
   Upper                       NR          50.1        1                                                                                                  
   Middle                      55.2        48.0        0.954 (0.599--1.518)   0.841                                                                       
   Lower                       81.7        53.1        0.912 (0.551--1.510)   0.720                                                                       
  Tumor length                                                                0.021[\*](#tfn5-ott-9-4257){ref-type="table-fn"}                            0.301
   ≤3 cm                       71.8        52.3        1                                                                           1                      
   \>3 cm                      43.2        46.0        1.348 (1.047--1.737)                                                        1.146 (0.885--1.485)   
  TNM stage                                                                   \<0.001[\*](#tfn5-ott-9-4257){ref-type="table-fn"}                          \<0.001[\*](#tfn5-ott-9-4257){ref-type="table-fn"}
   I--II                       NR          62.4        1                                                                           1                      
   III                         30.9        32.4        2.525 (1.949--3.270)                                                        2.387 (1.814--3.141)   
  Treatment                                                                   0.019[\*](#tfn5-ott-9-4257){ref-type="table-fn"}                            0.950
   Surgery alone               66.8        52.5        1                                                                           1                      
   Surgery + RT/CT             36.3        38.6        1.417 (1.060--1.895)                                                        0.990 (0.729--1.346)   
  GPS                                                                                                                                                     
   0                           71.8        52.3        1                                                                           1                      
   1                           35.6        39.6        1.393 (1.027--1.889)   0.033[\*](#tfn5-ott-9-4257){ref-type="table-fn"}     1.111 (0.812--1.521)   0.511
   2                           27.2        23.4        1.823 (0.963--3.449)   0.065                                                1.879 (0.985--3.587)   0.056
  NLR                                                                         0.118                                                                       
   \<2                         65.6        52.4        1                                                                                                  
   ≥2                          48.6        46.0        1.223 (0.950--1.575)                                                                               
  Heavy smoking                                                               0.011[\*](#tfn5-ott-9-4257){ref-type="table-fn"}                            
   No                          NR          55.7        1                                                                                                  
   Yes                         44.1        43.0        1.396 (1.081--1.802)                                                                               
  Drinking                                                                    0.014[\*](#tfn5-ott-9-4257){ref-type="table-fn"}                            
   No                          81.7        54.3        1                                                                                                  
   Yes                         41.2        39.9        1.385 (1.068--1.797)                                                                               
  Heavy smoking and drinking                                                                                                                              
   Neither                     NR          57.4        1                                                                           1                      
   Either                      55.2        46.4        1.364 (1.005--1.852)   0.047[\*](#tfn5-ott-9-4257){ref-type="table-fn"}     1.301 (0.956--1.771)   0.094
   Both                        41.2        39.1        1.578 (1.160--2.148)   0.004[\*](#tfn5-ott-9-4257){ref-type="table-fn"}     1.392 (1.020--1.901)   0.037[\*](#tfn5-ott-9-4257){ref-type="table-fn"}

**Note:**

*P*\<0.05.

**Abbreviations:** OS, overall survival; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; NR, not reached; RT, radiotherapy; CT, chemotherapy; GPS, Glasgow Prognostic Score; NLR, neutrophil/lymphocyte ratio; TNM, Tumor-Node-Metastases.
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